4,5-Bis-acetoxymethyl-3-lauroyloxy-2-methyl-pyridin | 1562-13-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4,5-Bis-acetoxymethyl-3-lauroyloxy-2-methyl-pyridin
• 英文别名: 4,5-Bis-acetoxymethyl-3-lauryloxy-2-methyl-pyridin；3-o-Lauroylpyridoxol diacetate；[4,5-bis(acetyloxymethyl)-2-methylpyridin-3-yl] dodecanoate
• CAS: 1562-13-6
• 化学式: C₂₄H₃₇NO₆
• 分子量: 435.561
• InChiKey: QPMYZGDVKZVLDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  31
• 可旋转键数：
  18
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  91.8
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] MACROMOLECULES FOR TREATING ATHEROSCLEROSIS<br/>[FR] MACROMOLÉCULES POUR LE TRAITEMENT DE L'ATHÉROSCLÉROSE
  申请人：UNIV RUTGERS

  公开号：WO2013188882A1

  公开（公告）日：2013-12-19

  The invention includes compounds of the formula I and formula II and salts thereof, as well as methods for using the compounds of formula I and formula II for treating atherosclerosis. The invention also includes compounds of formula III and (21) and salts thereof, as well as methods of using the compounds of formula III and (21) for treating atherosclerosis. The invention also includes methods of encapsulating molecules using the compounds of the invention.

  该发明包括公式I和公式II的化合物及其盐，以及使用公式I和公式II的化合物治疗动脉粥样硬化的方法。该发明还包括公式III和(21)的化合物及其盐，以及使用公式III和(21)的化合物治疗动脉粥样硬化的方法。该发明还包括使用该发明的化合物对分子进行封装的方法。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• AMPHIPHILIC MACROMOLECULES AND METHODS OF USE THEREOF
  申请人：RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

  公开号：US20160068467A1

  公开（公告）日：2016-03-10

  Certain embodiments of the invention provide a compound of formula (I): A-X—Y—Z—R 1 (I), or a salt thereof, wherein A, X, Y, Z and R 1 have any of the values defined in the specification, and methods of use thereof. For example, certain embodiments of the invention provide a method for inhibiting atherosclerosis or atherosclerotic development in a mammal, comprising administering to the mammal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

  本发明的某些实施例提供了化合物的结构式(I):A-X—Y—Z—R1(I)，或其盐，其中A、X、Y、Z和R1具有规范中定义的任何值，以及其使用方法。例如，本发明的某些实施例提供了一种方法，用于抑制哺乳动物中的动脉粥样硬化或动脉粥样硬化的发展，包括向哺乳动物施用化合物的有效量结构式(I)，或其药用盐。
• THERAPEUTIC HYPERBRANCHED POLYGLYCEROL ENCAPSULATED BIOMOLECULES
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160361425A1

  公开（公告）日：2016-12-15

  Methods for modifying therapeutic agents such as therapeutic biomolecules, such as proteins for improved oral, rectal or transmucosal delivery, as well as compositions made using such methods and methods of administering such compositions to a subject, are disclosed. Specifically, the therapeutic agents are conjugated to hyperbranched polymers (HBPs), such as hyperbranched polyglycerol (HPG). When such conjugates are administered orally to a subject, the HBP protects the therapeutic agent from the acid environment of the stomach and protease attack in the gastro-intestinal tract, while facilitating the absorption of the therapeutic agent in the higher pH environment of the intestines. The methods and compositions are useful for the improved administration of a variety of therapeutic agents to a subject.

  本发明涉及改进口服、直肠或黏膜透传输的治疗生物分子（例如蛋白质）的方法，以及使用这些方法制备的组合物和将这些组合物用于治疗的方法。具体而言，本发明将治疗生物分子与高分支聚合物（HBPs）如高分支聚甘油（HPG）共轭。当这种共轭物被口服给予受试者时，HBP可以保护治疗生物分子免受胃酸环境和胃肠道的蛋白酶攻击，同时促进治疗生物分子在肠道更高的pH环境中的吸收。这些方法和组合物可用于改善给予受试者各种治疗生物分子的途径。
• Segmented degradable polymers and conjugates made therefrom
  申请人：Nektar Therapeutics

  公开号：EP2319542A2

  公开（公告）日：2011-05-11

  The present invention provides, among other things, segmented, degradable polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains divided or separated by one or more degradable linkages into polymer segments having a molecular weight suitable for renal clearance. The polymeric reagents can have a substantially linear structure, a branched structure, or a multiarm structure. Each structure includes one or more linkages capable of degradation in vivo.

  本发明除其他外提供了适合与生物活性剂反应形成共轭物的分段式可降解聚合物试剂，这些聚合物试剂由一条或多条聚合物链组成，这些聚合物链被一条或多条可降解链节分割或分离成分子量适合肾脏清除的聚合物段。聚合物试剂可具有基本线性结构、支链结构或多臂结构。每种结构都包括一种或多种可在体内降解的连接。